{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:44:00Z","timestamp":1761101040354},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2011,1,15]],"date-time":"2011-01-15T00:00:00Z","timestamp":1295049600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1007\/s00262-010-0966-2","type":"journal-article","created":{"date-parts":[[2011,1,14]],"date-time":"2011-01-14T16:15:02Z","timestamp":1295021702000},"page":"599-607","source":"Crossref","is-referenced-by-count":3,"title":["Immunocompetent cell functions in Ph+ acute lymphoblastic leukemia patients on prolonged Imatinib maintenance treatment"],"prefix":"10.1007","volume":"60","author":[{"given":"Roberta","family":"Maggio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Peragine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Stefania","family":"De Propris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loredana","family":"Elia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Della Starza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Intoppa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Laura","family":"Milani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Guarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Fo\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,1,15]]},"reference":[{"key":"966_CR1","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1182\/blood-2009-08-237404","volume":"115","author":"K Vandyke","year":"2010","unstructured":"Vandyke K, Fitter S, Dewar AL, Hughes TP, Zannettino AC (2010) Dysregulation of bone remodeling by imatinib mesylate. Blood 115:766\u2013774","journal-title":"Blood"},{"key":"966_CR2","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMoa020150","volume":"347","author":"JF Apperley","year":"2002","unstructured":"Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, Chase A, Chessells JM, Colombat M, Dearden CE, Dimitrijevic S, Mahon FX, Marin D, Nikolova Z, Olavarria E, Silberman S, Schultheis B, Cross NC, Goldman JM (2002) Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor. N Engl J Med 347:481\u2013487","journal-title":"N Engl J Med"},{"key":"966_CR3","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","volume":"347","author":"GD Demetri","year":"2002","unstructured":"Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472\u2013480","journal-title":"N Engl J Med"},{"key":"966_CR4","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood-2004-07-2527","volume":"105","author":"R Seggewiss","year":"2005","unstructured":"Seggewiss R, Lore K, Greiner E, Magnusson MK, Price DA, Douek DC, Dunbar CE, Wiestner A (2005) Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 105:2473\u20132479","journal-title":"Blood"},{"key":"966_CR5","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood-2003-12-4266","volume":"104","author":"AB Dietz","year":"2004","unstructured":"Dietz AB, Souan L, Knutson GJ, Bulur PA, Litzow MR, Vuk-Pavlovic S (2004) Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 104:1094\u20131099","journal-title":"Blood"},{"key":"966_CR6","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1182\/blood-2006-04-018705","volume":"108","author":"S Mumprecht","year":"2006","unstructured":"Mumprecht S, Matter M, Pavelic V, Ochsenbein AF (2006) Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections. Blood 108:3406\u20133413","journal-title":"Blood"},{"key":"966_CR7","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s00262-006-0232-9","volume":"56","author":"J Chen","year":"2007","unstructured":"Chen J, Schmitt A, Chen B, Rojewski M, Ringhoffer M, von Harsdorf S, Greiner J, Guillaume P, Dohner H, Bunjes D, Schmitt M (2007) Imatinib impairs CD8+ T lymphocytes specifically directed against the leukemia-associated antigen RHAMM\/CD168 in vitro. Cancer Immunol Immunother 56:849\u2013861","journal-title":"Cancer Immunol Immunother"},{"key":"966_CR8","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1189\/jlb.0705419","volume":"79","author":"N Boissel","year":"2006","unstructured":"Boissel N, Rousselot P, Raffoux E, Cayuela JM, Soulier J, Mooney N, Charron D, Dombret H, Toubert A, Rea D (2006) Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation. J Leukocyte Biol 79:747\u2013756","journal-title":"J Leukocyte Biol"},{"key":"966_CR9","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/sj.leu.2403401","volume":"8","author":"K Cwynarski","year":"2004","unstructured":"Cwynarski K, Laylor R, Macchiarulo E, Goldman J, Lombardi G, Melo JV, Dazzi F (2004) Imatinib inhibits the activation and the proliferation of normal T lymphocytes in vitro. Leukemia 8:1332\u20131339","journal-title":"Leukemia"},{"key":"966_CR10","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/14653240802317639","volume":"10","author":"R Seggewiss","year":"2008","unstructured":"Seggewiss R, Price DA, Purbhoo MA (2008) Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an update. Cytotherapy 10:633\u2013641","journal-title":"Cytotherapy"},{"key":"966_CR11","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.4049\/jimmunol.178.4.2028","volume":"178","author":"P Sinai","year":"2007","unstructured":"Sinai P, Berg RE, Haynie JM, Egorin MJ, Ilaria RL Jr, Forman J (2007) Imatinib mesylate inhibits antigen-specific memory CD8 T cell responses in vivo. J Immunology 178:2028\u20132037","journal-title":"J Immunology"},{"key":"966_CR12","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1158\/1078-0432.CCR-04-1713","volume":"11","author":"S Appel","year":"2005","unstructured":"Appel S, Rupf A, Weck MM, Schoor O, Brummendorf TH, Weinschenk T, Grunebach F, Brossart P (2005) Effects of imatinib on monocyte-derived dendritic cells are mediated by inhibition of nuclear factor-B and Akt signaling pathways. Clin Cancer Res 11:1928\u20131940","journal-title":"Clin Cancer Res"},{"key":"966_CR13","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1182\/blood-2003-03-0975","volume":"103","author":"S Appel","year":"2004","unstructured":"Appel S, Boehmler AM, Grunebach F, Muller MR, Rupf A, Weck MM, Hartmann U, Reichardt VL, Kanz L, Brummendorf TH, Brossart P (2004) Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. Blood 103:538\u2013544","journal-title":"Blood"},{"key":"966_CR14","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1182\/blood-2003-10-3475","volume":"103","author":"J Taieb","year":"2004","unstructured":"Taieb J, Maruyama K, Borg C, Terme M, Zitvogel L (2004) Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo. Blood 103:1966\u20131967","journal-title":"Blood"},{"key":"966_CR15","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1038\/sj.leu.2404315","volume":"20","author":"R Wehner","year":"2006","unstructured":"Wehner R, Wendisch M, Schakel K, Bornhauser M, Platzbecker U, Mohr B, Temme A, Bachmann M, Rieber EP, Schmitz M (2006) Imatinib mesylate does not impair the immunogenicity of human myeloid blood dendritic cells. Leukemia 20:1629\u20131632","journal-title":"Leukemia"},{"key":"966_CR16","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1182\/blood-2004-01-0027","volume":"105","author":"H Wang","year":"2005","unstructured":"Wang H, Cheng F, Cuenca A, Horna P, Zheng Z, Bhalla K, Sotomayor EM (2005) Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance. Blood 105:1135\u20131143","journal-title":"Blood"},{"key":"966_CR17","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1097\/01.cco.0000245317.82391.1b","volume":"18","author":"A Vitale","year":"2006","unstructured":"Vitale A, Guarini A, Chiaretti S, Fo\u00e0 R (2006) The changing scene of adult acute lymphoblastic leukemia. Curr Opin Oncol 18:652\u2013659","journal-title":"Curr Opin Oncol"},{"key":"966_CR18","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1365-2141.2010.08246.x","volume":"150","author":"JM Rowe","year":"2010","unstructured":"Rowe JM (2010) Prognostic factors in adult acute lymphoblastic leukaemia. Br J Haematol 150:389\u2013405","journal-title":"Br J Haematol"},{"key":"966_CR19","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1097\/01.cco.0000357476.43164.6b","volume":"21","author":"OG Ottmann","year":"2009","unstructured":"Ottmann OG, Pfeifer H (2009) First-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia in adults. Curr Opin Oncol 21:S43\u2013S46","journal-title":"Curr Opin Oncol"},{"key":"966_CR20","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1182\/blood-2006-10-052746","volume":"109","author":"M Vignetti","year":"2007","unstructured":"Vignetti M, Fazi P, Cimino G, Martinelli G, Di Raimondo F, Ferrara F, Meloni G, Ambrosetti A, Quarta G, Pagano L, Rege-Cambrin G, Elia L, Bertieri R, Annino L, Fo\u00e0 R, Baccarani M, Mandelli F (2007) Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell\u2019Adulto (GIMEMA) LAL0201-B protocol. Blood 109:3676\u20133678","journal-title":"Blood"},{"key":"966_CR21","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.2005.03.2177","volume":"24","author":"M Yanada","year":"2006","unstructured":"Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, Kobayashi T, Ueda Y, Takeuchi M, Miyawaki S, Maruta A, Emi N, Miyazaki Y, Ohtake S, Jinnai I, Matsuo K, Naoe T, Ohno R, Japan Adult Leukemia Study Group (2006) High complete remission rate and promising outcome by combination of Imatinib and chemotherapy for newly diagnosed BCR-ABL-Positive acute lymphoblastic leukemia: a phase II study by the Japan adult leukemia study group. J Clin Oncol 24:460\u2013466","journal-title":"J Clin Oncol"},{"key":"966_CR22","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2141.2008.07377.x","volume":"143","author":"M Yanada","year":"2008","unstructured":"Yanada M, Sugiura I, Takeuchi J, Akiyama H, Maruta A, Ueda Y, Usui N, Yagasaki F, Yujiri T, Takeuchi M, Nishii K, Kimura Y, Miyawaki S, Narimatsu H, Miyazaki Y, Ohtake S, Jinnai I, Matsuo K, Naoe T, Ohno R, Japan Adult Leukemia Study Group (2008) Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy. Br J Haematol 143:503\u2013510","journal-title":"Br J Haematol"},{"key":"966_CR23","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1038\/sj.leu.2403062","volume":"17","author":"UJ Scheuring","year":"2003","unstructured":"Scheuring UJ, Pfeifer H, Wassmann B, Br\u00fcck P, Gehrke B, Petershofen EK, Gschaidmeier H, Hoelzer D, Ottmann OG (2003) Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) during imatinib treatment. Leukemia 17:1700\u20131706","journal-title":"Leukemia"},{"key":"966_CR24","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/sj.leu.2400912","volume":"12","author":"G Todeschini","year":"1998","unstructured":"Todeschini G, Tecchio C, Meneghini V, Pizzolo G, Veneri D, Zanotti R, Ricetti MM, Solero P, April F, Perona G (1998) Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin. Leukemia 12:144\u2013149","journal-title":"Leukemia"},{"key":"966_CR25","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1182\/blood-2008-12-191254","volume":"113","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Rosti G, Castagnetti F, Haznedaroglu I, Porkka K, Abruzzese E, Alimena G, Ehrencrona H, Hjorth-Hansen H, Kairisto V, Levato L, Martinelli G, Nagler A, Lanng Nielsen J, Ozbek U, Palandri F, Palmieri F, Pane F, Rege-Cambrin G, Russo D, Specchia G, Testoni N, Weiss-Bjerrum O, Saglio G, Simonsson B (2009) Comparison of imatinib 400\u00a0mg and 800\u00a0mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European Leukemia Net Study. Blood 113:4497\u20134504","journal-title":"Blood"},{"key":"966_CR26","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038\u20131042","journal-title":"N Engl J Med"},{"key":"966_CR27","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1080\/10428190601101001","volume":"48","author":"R Maggio","year":"2007","unstructured":"Maggio R, Peragine N, Calabrese E, De Propris MS, Intoppa S, Della Starza I, Ariola C, Vitale A, Fo\u00e0 R, Guarini A (2007) Generation of functional dendritic cells (DC) in adult acute lymphoblastic leukaemia; Rationale for a DC-based vaccination program for patients in complete hematological remission. Leuk Lymphoma 48:302\u2013310","journal-title":"Leuk Lymphoma"},{"key":"966_CR28","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1002\/eji.200526298","volume":"35","author":"UE H\u00f6pken","year":"2005","unstructured":"H\u00f6pken UE, Lehmann I, Droese J, Lipp M, Sch\u00fcler T, Rehm A (2005) The ratio between dendritic cells and T cells determines the outcome of their encounter: proliferation versus deletion. Eur J Immunol 35:2851\u20132863","journal-title":"Eur J Immunol"},{"key":"966_CR29","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(05)17945-8","volume":"365","author":"M Bocchia","year":"2005","unstructured":"Bocchia M, Gentili S, Abruzzese E, Fanelli A, Iuliano F, Tabilio A, Amabile M, Forconi F, Gozzetti A, Raspadori D, Amadori S, Lauria F (2005) Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 365:657\u2013662","journal-title":"Lancet"},{"key":"966_CR30","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/sj.leu.2404029","volume":"20","author":"M Bocchia","year":"2006","unstructured":"Bocchia M, Abruzzese E, Forconi F, Ippoliti M, Trawinska MM, Pirrotta MT, Raspadori D, Tozzi M, Gozzetti A, Lauria F (2006) Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia. Leukemia 20:142\u2013143","journal-title":"Leukemia"},{"key":"966_CR31","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.1182\/blood-2007-12-128397","volume":"111","author":"CI Chen","year":"2008","unstructured":"Chen CI, Maecker HT, Lee PP (2008) Development and dynamics of robust T-cell responses to CML under imatinib treatment. Blood 111:5342\u20135349","journal-title":"Blood"},{"key":"966_CR32","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1182\/blood-2009-06-230391","volume":"115","author":"G Riva","year":"2010","unstructured":"Riva G, Luppi M, Barozzi P, Quadrelli C, Basso S, Vallerini D, Zanetti E, Morselli M, Forghieri F, Maccaferri M, Volzone F, Del Giovane C, D\u2019Amico R, Locatelli F, Torelli G, Comoli P, Potenza L (2010) Emergence of BCR-ABL-specific cytotoxic T cells in the bone marrow of patients with Ph\u00a0+\u00a0acute lymphoblastic leukemia during long-term Imatinib mesylate treatment. Blood 115:1512\u20131518","journal-title":"Blood"},{"key":"966_CR33","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/cncr.22881","volume":"110","author":"PP Piccaluga","year":"2007","unstructured":"Piccaluga PP, Paolini S, Martinelli G (2007) Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Cancer 110:1178\u20131186","journal-title":"Cancer"},{"key":"966_CR34","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1053\/j.seminhematol.2008.09.009","volume":"46","author":"S Jeha","year":"2009","unstructured":"Jeha S (2009) New therapeutic strategies in acute lymphoblastic leukemia. Semin Hematol 46:76\u201388","journal-title":"Semin Hematol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-010-0966-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-010-0966-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-010-0966-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T04:01:51Z","timestamp":1712116911000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-010-0966-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,15]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["966"],"URL":"https:\/\/doi.org\/10.1007\/s00262-010-0966-2","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,15]]}}}